Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma.

Su DH, Chang SH, Chang TC.

Clin Endocrinol (Oxf). 2015 Feb;82(2):286-94. doi: 10.1111/cen.12511. Epub 2014 Jul 7.

2.

Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.

Wu MH, Shen WT, Gosnell J, Duh QY.

Head Neck. 2015 Sep;37(9):1336-43. doi: 10.1002/hed.23747. Epub 2014 Oct 29.

PMID:
24821456
3.

Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up.

Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A.

World J Surg. 2012 Jun;36(6):1274-8. doi: 10.1007/s00268-012-1423-5.

PMID:
22270990
4.

Management and outcome of recurrent well-differentiated thyroid carcinoma.

Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL.

Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24.

PMID:
15262757
5.

The impact of nodal status on outcome in older patients with papillary thyroid cancer.

Nixon IJ, Wang LY, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I.

Surgery. 2014 Jul;156(1):137-46. doi: 10.1016/j.surg.2014.03.027. Epub 2014 May 27.

PMID:
24878458
6.
7.

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Mazzaferri EL, Jhiang SM.

Am J Med. 1994 Nov;97(5):418-28. Erratum in: Am J Med 1995 Feb;98(2):215.

PMID:
7977430
8.

The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.

Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I.

Thyroid. 2012 Sep;22(9):884-9. doi: 10.1089/thy.2011.0535. Epub 2012 Jul 24.

9.

Papillary thyroid carcinoma: factors influencing recurrence and survival.

Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M.

Ann Surg Oncol. 2008 May;15(5):1518-22. doi: 10.1245/s10434-008-9859-4. Epub 2008 Mar 7.

PMID:
18324441
10.

Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).

Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, Sack H.

Cancer. 1996 Jan 1;77(1):172-80.

11.

Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.

Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH.

Cancer. 2003 Jul 1;98(1):31-40.

12.

Impact of invasive extranodal extension on the prognosis of patients with papillary thyroid carcinoma.

Moritani S.

Thyroid. 2014 Dec;24(12):1779-83. doi: 10.1089/thy.2014.0167.

PMID:
25157399
13.

Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size.

Meixner M, Hellmich M, Dietlein M, Kobe C, Schicha H, Schmidt M.

Nuklearmedizin. 2013;52(3):71-80. doi: 10.3413/Nukmed-0530-12-09. Epub 2013 Mar 13.

PMID:
23483137
14.

Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.

Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini E.

Minerva Endocrinol. 2013 Sep;38(3):269-79.

PMID:
24126547
15.

Outcomes in patients with poorly differentiated thyroid carcinoma.

Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, Patel SG, Tuttle RM, Shah JP, Ganly I.

J Clin Endocrinol Metab. 2014 Apr;99(4):1245-52. doi: 10.1210/jc.2013-3842. Epub 2014 Feb 10.

PMID:
24512493
16.

Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size.

Ito Y, Fukushima M, Kihara M, Takamura Y, Kobayashi K, Miya A, Miyauchi A.

Endocr J. 2012;59(6):457-64. Epub 2012 Mar 8.

17.

Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.

Verburg FA, Mäder U, Luster M, Reiners C.

Eur J Endocrinol. 2009 Apr;160(4):619-24. doi: 10.1530/EJE-08-0805. Epub 2009 Jan 21.

18.

The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.

Mihailovic J, Stefanovic L, Malesevic M, Markoski B.

Thyroid. 2009 Mar;19(3):227-32. doi: 10.1089/thy.2008.0186.

PMID:
19265493
19.

TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.

Suman P, Wang CH, Abadin SS, Block R, Raghavan V, Moo-Young TA, Prinz RA, Winchester DJ.

Endocr Pract. 2016 Jul;22(7):822-31. doi: 10.4158/EP151088.OR. Epub 2016 Mar 28.

PMID:
27018620
20.

Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer.

Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA.

J Clin Oncol. 2015 Jul 20;33(21):2370-5. doi: 10.1200/JCO.2014.59.8391. Epub 2015 Jun 15.

PMID:
26077238

Supplemental Content

Support Center